Dr. Jennifer Bath, an expert in antibody discovery, as well as translational work in infectious disease, explains why leaving a tenured professorship was a price worth paying to become the CEO of ImmunoPrecise Antibodies (IPA). Under her leadership, and with B Cell Select, a proprietary discovery platform at her command, IPA is developing a therapeutic antibody cocktail called, Polytope , that has the potential to not only treat current strains of Covid-19, but also emerging variants. She also a...

Cortexyme CEO, Casey Lynch, discusses her life-long passion for finding treatments for neurodegenerative diseases in general, and Alzheimer’s in particular. She tells how her experience over the years, in different labs, and in different companies taught her that the science behind proposed Alzheimer’s interventions was missing the forest for the trees, and that an entirely different hypothesis suggested that one of the root causes of Alzheimer’s is a history of infection with a bug that causes ...

Medigene CEO, Dolores Schendel, takes us from her Midwestern roots to the helm of Bavaria’s Medigene AG. Along the way, she explains how her training at the hands of immunotherapy pioneers led to her recent move to deploy a novel molecular switch which protects and energizes Medigene’s TCR-T cells in their attack on solid tumors. (Plus, hear her talk about winning the prestigious Bavarian Order of Merit! For what, you ask? Well – give a listen…)

Dr. Coffey explains how a phenomenon first observed over a 100 years ago – that a systemic infection can cure cancer – became the blanket term for a treatment modality bearing his company’s name. From being a lab rat studying reovirus one day, to a company co-founder the next, Coffey’s rise through the corporate ranks (he started out as VP of Product Development), and his pursuit of the scientific secrets that revealed the true activity of his lead asset (hint: lysing tumor cells ain’t it) set O...

BiomX co-founder, Jonathan Solomon, gained his early scientific training in physics, and electrical engineering during a ten-year stint in an Israeli army special forces unit – which he can’t really talk about. But what he can talk about is how – with his taste for adventure, a Harvard MBA, and a famous Israeli scientist for a mother – he became the Chief Executive Officer of Biomx, a publicly held company that is harnessing naturally occurring phage to kill pathogenic bacteria in a broad variet...

Dr. Caligiuri describes his journey from being a liberal arts major at a college in upstate New York, to being a Stanford trained MD, to his current position as President of City of Hope National Medical Center. Along the way Caligiuri shares his thoughts on training to be a hematologist in the late ‘80s – at a time when there were no curative therapies, and such a calling was daunting at best – to his finding a cherished mentor that put him on the road to becoming one of the top NK cell experts...